A looming shortage of doses for low- and moderate-income countries puts increased pressure on Novavax to obtain regulatory approvals for global manufacturing.
Related posts:
Trump to prioritize older adults for Covid vaccines, release all doses
Biden calls for speeding up release of Covid shots
Surgeon general defends integrity of Covid-19 numbers
First U.S. case of infectious Covid variant reported in Colorado
Republicans hit mute on Obamacare wars
Drug industry pushes FDA to solve growing inspection backlog
CDC delays guidelines for vaccinated people
White House, state officials scramble to get docs’ help with lagging vaccination effort
CDC panel endorses use of Pfizer Covid-19 vaccine in young teens
CDC chief said change on mask guidance not due to public pressure
FDA authorizes Pfizer Covid booster for 16-, 17-year-olds
De Blasio defends vaccine mandates, points to effectiveness in NYC
